• Illustration showing two types of gel adjuvants: left is a particulate gel adjuvant with yellow spheres and blue bacterial antigens, and right is a network gel adjuvant with blue viral antigens.
  • Illustration showing two types of adjuvants: a bacterium labeled 'Particulate Adjuvant' on the left with surrounding yellow particles, and a virus labeled 'Network Adjuvant' on the right with a purple virus surrounded by blue strands and yellow particles.
  • 3D illustration comparing a particulate adjuvant with a bacterium on the left and a network adjuvant with a virus on the right.
  • Illustration comparing particle gel vaccine on the left with network gel vaccine on the right, featuring yellow spheres and blue structures.
  • Illustration comparing particulate gel adjuvant with a bacterium on the left, and networked gel adjuvant with a virus on the right, showing structural components.
  • Illustration comparing particulate gel adjuvant and networked gel adjuvant, featuring a green bacterium alongside blue and purple spherical structures.
  • Visualization of SDA 701, a particulate polymer gel showcasing cross-linked hydrogel particles in various sizes.
Diagram illustrating the SDA BIO Vaccine Adjuvant Selection Map, outlining steps for selecting optimal adjuvants based on immunological goals and target species.
SDA 701 Particulate Microgel product display with polymer-based formulation details.

SDA 701 Particulate Microgel

SDA 701 vaccine adjuvant graphic showing a blue polymer gel particle structure with text about its features and effectiveness in vaccine formulation.
Diagram illustrating the mechanism of action of SDA 701A adjuvant, detailing steps from antigen delivery to coordinated immune response activation. Includes sections on antigen delivery, polymer microgel encapsulation, APC recruitment and activation, and types of immunity: humoral, cellular, and mucosal.
  • SDA 701 A is polymer based particulate microgel concentrates, fully pre-formed gel, contracted particles. SDA 701 B is fully pre-formed gel but relatively loose and open for antigen dilution induction of gel contraction. SDA 701C is latent gel for antigen dilution induction of gel formation and contraction
  • Ready to combine with aqueous antigen at ratio of 1 part of oil phase to 9 or more parts of aqueous antigen
  • Oil Drop Particle size = ~30 nm and Polymer Particle Size of 200-300 nm
  • Nearly transparent and colorless
Line graph displaying three different data sets represented by green, blue, and orange lines, showing variations across two axes with logarithmic scaling.
Two glass vials side by side: left contains a white microgel labeled 'SDA 701B Microgel' and right contains a clear liquid labeled 'SDA 701B Vaccine'.
Two glass vials containing different solutions, with the left vial having a cloudy liquid and the right vial containing a clear liquid.

SDA 702 Network Microgel

SDA 702 Networked Hydrogel, a cross-linked polymeric matrix for antigen delivery, shown with blue and orange spheres in a structured pattern.
  • SDA 702 A is fully pre-formed gel but relatively loose and open for antigen dilution induction of gel contraction. SDA 702 B is latent gel for antigen dilution induction of gel formation and contraction
  • Ready to combine with aqueous antigen at ratio of 1 part of oil phase to 9 or more parts of aqueous antigen
  • Single Oil Particle size = ~100 nm
  • Between milky and colloidal white
Two bottles labeled 'SDA 702B Microgel' and 'SDA 702B Vaccine' filled with clear liquid, placed against a dark background.

SDA702 A & B Gel Vaccines with Purified or Crude Antigen

Table comparing various platforms for microgel and gel hybrid particle types, detailing type descriptions, structure and oil content, appearance, depot strength, and best fit for antigens.

SDA 703 Network Microgel

3D illustration of a cross-linking polymer network encapsulating various colored spheres, representing antigens, with a description of its use in enhancing immune response and vaccine efficacy.
Three glass bottles filled with milk, each with a blue screw-on cap.

SDA 703 A is fully pre-formed gel but relatively loose and open for antigen dilution induction of gel contraction. SDA 703 B is latent gel for antigen dilution induction of gel formation and contraction

  • Ready to combine with aqueous antigen at ratio of 1 part of oil phase to 9 or more parts of aqueous antigen
  • Single Oil Particle size = ~100 nm
  • Milky white
Illustration depicting the mechanism of action for SDA 703 adjuvant, including steps for antigen delivery, polymer microgel formation, and APC recruitment and activation, leading to a coordinated immune response involving humoral, cellular, and mucosal immunity.